Role of biomarkers to predict outcomes and response to therapy

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 1, 2010, Pages 97-101

  Lotan, Yair ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bladder cancer; Molecular markers

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; GEMCITABINE; PACLITAXEL; TRASTUZUMAB;

BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT RESPONSE; UROTHELIAL CARCINOMA OF THE BLADDER;

BIOLOGICAL MARKERS; HUMANS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 72549108182     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.03.017     Document Type: Review

References (46)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission.
3. American College of Surgeons. Commission on Cancer National Cancer Database. Available at: http://www.facs.org/cancer/ncdb/index.html. Accessed September 7, 2005.
4. Shariat S.F., Karakiewicz P.I., Palapattu G.S., et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: A contemporary series from the Bladder Cancer Research Consortium. J Urol 176 (2006) 2414-2422 ; Discussion 2422.
5. Shariat S.F., Palapattu G.S., Karakiewicz P.I., et al. Discrepancy between clinical and pathologic stage: Impact on prognosis after radical cystectomy. Eur Urol 51 (2007) 137-149 Discussion 149-51
6. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 19 (2001) 666-675
7. Calabro F., and Sternberg C.N. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder Cancer. Eur Urol 55 (2008) 348-358
8. Bellmunt J., Albiol S., Suarez C., et al. Optimizing therapeutic strategies in advanced bladder cancer: Update on chemotherapy and the role of targeted agents. Crit Rev Oncol Hematol 69 (2008) 211-222
9. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48 (2005) 202-205 Discussion 205-6
10. Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst Rev (2006) 2:CD006018.
11. David K.A., Milowsky M.I., Ritchey J., et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: A report from the National Cancer Data Base. J Urol 178 (2007) 451-454
12. Bochner B.H., Kattan M.W., and Vora K.C. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 24 (2006) 3967-3972
13. Karakiewicz P.I., Shariat S.F., Palapattu G.S., et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 176 (2006) 1354-1361 ; Discussion 1361-2.
14. Pepe M.S., Feng Z., Janes H., et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: Standards for study design. J Natl Cancer Inst 100 (2008) 1432-1438
15. Ransohoff D.F. How to improve reliability and efficiency of research about molecular markers: Roles of phases, guidelines, and study design. J Clin Epidemiol 60 (2007) 1205-1219
16. Bensalah K., Montorsi F., and Shariat S.F. Challenges of cancer biomarker profiling. Eur Urol 52 (2007) 1601-1609
17. Bolenz C., and Lotan Y. Molecular biomarkers for urothelial carcinoma of the bladder: Challenges in clinical use. Nat Clin Pract Urol 5 (2008) 676-685
18. Shariat S.F., Karam J.A., and Lerner S.P. Molecular markers in bladder cancer. Curr Opin Urol 18 (2008) 1-8
19. Esrig D., Elmajian D., Groshen S., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331 (1994) 1259-1264
20. Malats N., Bustos A., Nascimento C.M., et al. P53 as a prognostic marker for bladder cancer: A meta-analysis and review. Lancet Oncol 6 (2005) 678-686
21. Lerner S.P. Bladder cancer clinical trials. Urol Oncol 23 (2005) 275-279
22. Hernandez S., Lopez-Knowles E., Lloreta J., et al. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: Independent distribution and lack of association with prognosis. Clin Cancer Res 11 (2005) 5444-5450
23. George B, Datar RH, Wu L, et al. p53 Gene and protein status: The role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol 200;25:5352-8.
24. Wu X.R. Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 5 (2005) 713-725
25. Karam J.A., Lotan Y., Karakiewicz P.I., et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 8 (2007) 128-136
26. Shariat S.F., Zlotta A.R., Ashfaq R., et al. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 20 (2007) 445-459
27. Shariat S.F., Karakiewicz P.I., Ashfaq R., et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 112 (2008) 315-325
28. Shariat S.F., Tokunaga H., Zhou J., et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22 (2004) 1014-1024
29. Shariat S.F., Karakiewicz P.I., Ashfaq R., et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 112 (2008) 315-325
30. Shariat S.F., Karakiewicz P.I., Fradet Y., et al. Combination of cell cycle regulating biomarkers improve prognosis in patients with organ confined urothelial cancer at radical cystectomy. J Urol 179 (2008) 578 (Abstract)
31. Bellmunt J., Paz-Ares L., Cuello M., et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Spanish Oncology Genitourinary Group. Ann Oncol 18 (2007) 522-528
32. Als A.B., Dyrskjot L., von der Maase H., et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 13 (2007) 4407-4414
33. Therasse P., Carbonnelle S., Bogaerts J., et al. Clinical trials design and treatment tailoring: General principles applied to breast cancer research. Crit Rev Oncol Hematol 59 (2006) 98-105
34. Sternberg C.N., de Mulder P.H., Schornagel J.H., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19 (2001) 2638-2646
35. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib vs. interferon-α in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
36. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. TARGET Study Group. N Engl J Med 356 (2007) 125-134
37. Mellon K., Wright C., Kelly P., et al. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 153 (1995) 919-925
38. Kassouf W., Luongo T., Brown G., et al. Schedule-dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol 176 (2006) 787-792
39. Philips G.K., Halabi S., Sanford B.L., et al. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: Results of the Cancer and Leukaemia Group B 90102. BJU Int 101 (2008) 20-25
40. Gandour-Edwards R., Lara Jr. P.N., Folkins A.K., et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?. Cancer 95 (2002) 1009-1015
41. Sato K., Moriyama M., Mori S., et al. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 70 (1992) 2493-2498
42. Kruger S., Weitsch G., Buttner H., et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic implications. Int J Cancer 102 (2002) 514-518
43. Kolla S.B., Seth A., Singh M.K., et al. Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol 40 (2008) 321-327
44. Hussain M.H., MacVicar G.R., Petrylak D.P., et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: Results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25 (2007) 2218-2224
45. Bradley D.A., Dunn R., Nanus D., et al. Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: Scientific rationale and study design. Clin Genitourin Cancer 5 (2007) 460-463
46. Sonpavde G., Jian W., Liu H., et al. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 27 (2009) 391-399